Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated at StockNews.com

by · The Cerbat Gem

StockNews.com began coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) in a report published on Wednesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald upped their price objective on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st.

Check Out Our Latest Research Report on VNDA

Vanda Pharmaceuticals Trading Up 3.7 %

Vanda Pharmaceuticals stock opened at $4.91 on Wednesday. The stock has a fifty day moving average price of $4.95 and a 200 day moving average price of $5.23. Vanda Pharmaceuticals has a 52 week low of $3.30 and a 52 week high of $6.75. The firm has a market capitalization of $285.75 million, a P/E ratio of -61.38 and a beta of 0.77.

Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) last announced its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter. Vanda Pharmaceuticals had a negative return on equity of 2.01% and a negative net margin of 6.00%. The company had revenue of $50.47 million for the quarter. As a group, equities analysts predict that Vanda Pharmaceuticals will post -0.49 EPS for the current year.

Institutional Trading of Vanda Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Sei Investments Co. lifted its position in Vanda Pharmaceuticals by 39.6% during the first quarter. Sei Investments Co. now owns 518,851 shares of the biopharmaceutical company’s stock valued at $2,132,000 after buying an additional 147,066 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in Vanda Pharmaceuticals during the 1st quarter worth $1,158,000. Acadian Asset Management LLC increased its holdings in Vanda Pharmaceuticals by 4.7% in the 1st quarter. Acadian Asset Management LLC now owns 2,370,335 shares of the biopharmaceutical company’s stock valued at $9,740,000 after purchasing an additional 107,203 shares in the last quarter. Monaco Asset Management SAM purchased a new position in Vanda Pharmaceuticals in the second quarter valued at about $1,090,000. Finally, Empowered Funds LLC lifted its stake in shares of Vanda Pharmaceuticals by 8.2% during the first quarter. Empowered Funds LLC now owns 201,283 shares of the biopharmaceutical company’s stock worth $827,000 after purchasing an additional 15,215 shares in the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

(Get Free Report)

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

Featured Articles